Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative breast cancer patients.
BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies
BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service.